RT Journal Article
SR Electronic
T1 Biologicals in childhood severe asthma: the European PERMEABLE survey on the <em>status quo</em>
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00143-2021
DO 10.1183/23120541.00143-2021
VO 7
IS 3
A1 Elisangela Santos-Valente
A1 Heike Buntrock-Döpke
A1 Rola Abou Taam
A1 Stefania Arasi
A1 Arzu Bakirtas
A1 Jaime Lozano Blasco
A1 Klaus Bønnelykke
A1 Mihai Craiu
A1 Renato Cutrera
A1 Antoine Deschildre
A1 Basil Elnazir
A1 Louise Fleming
A1 Urs Frey
A1 Monika Gappa
A1 Antonio Nieto García
A1 Kirsten Skamstrup Hansen
A1 Laurence Hanssens
A1 Karina Jahnz-Rozyk
A1 Milos Jesenak
A1 Sebastian Kerzel
A1 Matthias V. Kopp
A1 Gerard H. Koppelman
A1 Uros Krivec
A1 Kenneth A. MacLeod
A1 Mika Mäkelä
A1 Erik Melén
A1 Györgyi Mezei
A1 Alexander Moeller
A1 Andre Moreira
A1 Petr Pohunek
A1 Predrag Minić
A1 Niels W.P. Rutjes
A1 Patrick Sammut
A1 Nicolaus Schwerk
A1 Zsolt Szépfalusi
A1 Mirjana Turkalj
A1 Iren Tzotcheva
A1 Alexandru Ulmeanu
A1 Stijn Verhulst
A1 Paraskevi Xepapadaki
A1 Jakob Niggel
A1 Susanne Vijverberg
A1 Anke H. Maitland-van der Zee
A1 Uroš Potočnik
A1 Susanne M. Reinartz
A1 Cornelis M. van Drunen
A1 Michael Kabesch
YR 2021
UL http://openres.ersjournals.com/content/7/3/00143-2021.abstract
AB Introduction Severe asthma is a rare disease in children, for which three biologicals, anti-immunoglobulin E, anti-interleukin-5 and anti-IL4RA antibodies, are available in European countries. While global guidelines exist on who should receive biologicals, knowledge is lacking on how those guidelines are implemented in real life and which unmet needs exist in the field. In this survey, we aimed to investigate the status quo and identify open questions in biological therapy of childhood asthma across Europe.Methods Structured interviews regarding experience with biologicals, regulations on access to the different treatment options, drug selection, therapy success and discontinuation of therapy were performed. Content analysis was used to analyse data.Results We interviewed 37 experts from 25 European countries and Turkey and found a considerable range in the number of children treated with biologicals per centre. All participating countries provide public access to at least one biological. Most countries allow different medical disciplines to prescribe biologicals to children with asthma, and only a few restrict therapy to specialised centres. We observed significant variation in the time point at which treatment success is assessed, in therapy duration and in the success rate of discontinuation. Most participating centres intend to apply a personalised medicine approach in the future to match patients a priori to available biologicals.Conclusion Substantial differences exist in the management of childhood severe asthma across Europe, and the need for further studies on biomarkers supporting selection of biologicals, on criteria to assess therapy response and on how/when to end therapy in stable patients is evident.This study reveals enormous differences in therapy with biologicals for childhood severe asthma across Europe, and demonstrates the urgent need for harmonisation in medication choice, definition of therapy success and how/when to discontinue treatment https://bit.ly/3tnJMTY